Oral prenylation inhibition with lonafarnib in chronic hepatitis D infection: a proof-of-concept randomised, double-blind, placebo-controlled phase 2A trial

Christopher Koh, Theo Heller, Gitanjali Subramanya et al.|The Lancet Infectious Diseases|2015

Cited by 262